Kefir

1. What conditions has Kefir been studied for?

• Metabolic syndrome (effects on metabolic parameters and gut microbiota) in a 12-week randomized controlled trial (kefir vs unfermented milk).

• Overweight/obesity and weight management in overweight/obese premenopausal women on a non–energy-restricted, dairy-rich diet (8-week randomized trial: kefir vs milk vs control).

• Type 2 diabetes mellitus (glycemic control and lipids) in an 8-week randomized double-blind placebo-controlled trial (probiotic fermented milk/kefir vs conventional fermented milk).

• Hypercholesterolemia / dyslipidemia in mildly hypercholesterolemic men (randomized crossover trial, 4 weeks kefir vs milk).

• Inflammatory bowel disease (IBD) (ulcerative colitis and Crohn’s disease): fecal microflora and symptoms (4-week open-label randomized controlled trial).

• Gut microbiota modulation in healthy adults (Hungarian probiotic kefir “Biofir” vs traditional kefir control; 4-week intervention with follow-up).

• Antibiotic-associated diarrhea (AAD) prevention in children receiving antibiotics (double-blind randomized placebo-controlled trial; 14-day follow-up).

• Cancer survivorship (post-exercise recovery) in cancer survivors in an exercise program (12-week kefir after exercise vs control; outcomes included body composition, symptoms, and immune/metabolic markers).

• Intestinal permeability / barrier dysfunction in asymptomatic overweight adults (3-week crossover: kefir vs milk; serum zonulin as primary marker).

• Colorectal cancer chemotherapy side effects and quality of life (randomized controlled prospective interventional study).

2. Does it work in treating those conditions? Summarize the evidence.

• Metabolic syndrome: Within the kefir group, fasting insulin, HOMA-IR, TNF-α, IFN-γ, and systolic/diastolic blood pressure decreased over 12 weeks (p≤0.05). However, there were no significant differences versus unfermented milk (p>0.05), so evidence for a kefir-specific benefit is limited in this small trial (n=22).

• Weight loss (overweight/obesity): In an 8-week trial (n=75 randomized; 58 completed), both kefir and milk groups had greater reductions in weight, BMI, and waist circumference than control (all p<0.01), but kefir was not superior to milk. This suggests dairy addition (or study diet context) may explain much of the effect rather than kefir-specific microbes.

• Type 2 diabetes: In an 8-week double-blind trial (n=60), the kefir/probiotic fermented milk group had lower fasting blood glucose vs control after intervention (P=0.01) and HbA1c decreased within the probiotic group (P=0.001) and vs control after adjustment (P=0.02). Lipids did not significantly change. This provides moderate short-term evidence for improved glycemic control compared with another fermented milk.

• Cholesterol lowering: In mildly hypercholesterolemic men (n=13) over 4 weeks, kefir had no effect on total cholesterol, LDL-C, HDL-C, triglycerides, or cholesterol synthesis rate. This trial does not support kefir as a lipid-lowering agent, at least in the short term and at the studied dose/duration.

• IBD (Crohn’s disease/ulcerative colitis): In a 4-week open-label randomized trial (45 patients), stool Lactobacillus loads increased significantly in the kefir group (p=0.001 in ulcerative colitis; p=0.005 in Crohn’s). In Crohn’s disease, inflammatory markers (ESR, CRP) decreased and hemoglobin increased; bloating improved in the last 2 weeks (p=0.012) and “feeling good” improved (p=0.032). Because the study was open-label and short, results are suggestive but not definitive for clinical disease control.

• Antibiotic-associated diarrhea prevention: In children (n=125) followed for 14 days, kefir did not reduce diarrhea incidence (18% vs 21.9% placebo; RR 0.82; 95% CI 0.54–1.43). Evidence here indicates no clear benefit for AAD prevention in this setting.

• Intestinal permeability (zonulin): In a crossover study of 28 overweight adults, kefir produced a greater improvement in serum zonulin than milk (F=6.812, η2=0.275). Lipids and glucose improved similarly with both. This supports a potential kefir-specific effect on a barrier dysfunction marker, though zonulin is an indirect biomarker and clinical implications were not established.

• Cancer survivors (post-exercise): In a 12-week intervention (N=24), kefir was associated with improved lean body mass (6.3%, P=0.034), reduced depression/fatigue/gastric distress (all statistically significant), and reduced circulating LPS (35.4%, P=0.01), with changes in monocyte subsets. Promising but limited by small sample size and the context of concurrent structured exercise.

• Colorectal cancer chemotherapy side effects/QOL: The abstract reports that after chemotherapy the kefir group had more treatment-related gastrointestinal complaints (text truncated), suggesting possible worsening of GI symptoms in that study; details and statistical outcomes are not fully available from the provided abstract excerpt.

3. What health benefits does it have?

• Glycemic control (type 2 diabetes): Reduced fasting glucose vs control (P=0.01) and reduced HbA1c (within-group P=0.001; vs control P=0.02 after adjustment) over 8 weeks; no consistent lipid benefit in that trial.

• Possible improvements in insulin resistance/inflammation and blood pressure (metabolic syndrome): Decreases in fasting insulin, HOMA-IR, TNF-α, IFN-γ, and blood pressure within the kefir group over 12 weeks, though not significantly different from unfermented milk.

• Gut microbiota changes: In metabolic syndrome, kefir increased relative abundance of Actinobacteria (p=0.023). In IBD, stool Lactobacillus loads increased significantly; in healthy volunteers, probiotic kefir (Biofir) promoted “probiotic flora” growth compared with traditional kefir control (per authors’ conclusion).

• Intestinal barrier marker improvement: Greater improvement in serum zonulin with kefir than milk in overweight adults (crossover study), suggesting a potential benefit for barrier dysfunction.

• Symptoms/quality of life signals in specific populations: In Crohn’s disease, improvements in bloating and “feeling good” scores; in cancer survivors, improvements in depression, fatigue, and gastric distress alongside reduced LPS.

• Weight and waist reduction (not kefir-specific): Kefir supported reductions in weight/BMI/waist compared with control in a dairy-rich diet trial, but effects were similar to milk.

4. Does it have any downsides or side effects?

• May worsen GI complaints in some contexts: In the colorectal cancer chemotherapy study, the kefir group reportedly had more treatment-related gastrointestinal complaints (abstract text is incomplete, so the magnitude and specific symptoms are unclear).

• No benefit for preventing antibiotic-associated diarrhea: In children on antibiotics, kefir did not reduce diarrhea incidence vs placebo (RR 0.82; 95% CI 0.54–1.43). While not a “side effect,” it suggests limited utility for this purpose.

• Potential for GI intolerance (general consideration, not directly quantified in most abstracts): Several studies used relatively high volumes (e.g., 400 mL/day in IBD; 600 mL/day in diabetes trial). People with lactose intolerance or milk protein allergy could experience symptoms; however, these abstracts do not provide systematic adverse-event reporting beyond symptom diaries in some trials.

• Evidence limitations: Multiple studies are small, short-duration, or open-label, which increases uncertainty about both benefits and harms and makes rare adverse effects hard to detect.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not evaluate genetic variants or pharmacogenomic interactions with kefir (e.g., no stratification by genotype and no gene–diet interaction analyses).

• Lactase persistence/non-persistence (LCT-related genetics): Not studied in these abstracts, but it is a plausible modifier of tolerance to dairy-based kefir (GI symptoms could differ by lactase status). Fermentation may reduce lactose content, yet individual response would still vary; no direct evidence here.

• Other candidate gene interactions (e.g., lipid metabolism, inflammation): Not addressed in the abstracts, so no evidence-based claims can be made from this set.

References

1. Effects of Regular Kefir Consumption on Gut Microbiota in Patients with Metabolic Syndrome: A Parallel-Group, Randomized, Controlled Study
   Ezgi Bellikci-Koyu, Banu Pınar Sarer-Yurekli, Yakut Akyon, Fadime Aydin-Kose, Cem Karagozlu (2019)
2. Kefir drink leads to a similar weight loss, compared with milk, in a dairy-rich non-energy-restricted diet in overweight or obese premenopausal women: a randomized controlled trial
   Yasamin Fathi, Shiva Faghih, Mohammad Javad Zibaeenezhad, Sayed Hamid Reza Tabatabaei (2016)
3. Effect of probiotic fermented milk (kefir) on glycemic control and lipid profile in type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial
   Alireza Ostadrahimi, Akbar Taghizadeh, Majid Mobasseri, Nazila Farrin, Laleh Payahoo (2015)
4. Kefir consumption does not alter plasma lipid levels or cholesterol fractional synthesis rates relative to milk in hyperlipidemic men: a randomized controlled trial [ISRCTN10820810]
   Marie-Pierre St-Onge, Edward R Farnworth, Tony Savard, Denise Chabot, Akier Mafu (2002)
5. Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: A randomized controlled trial
   İlkay Yılmaz, M Enver Dolar, Haydar Özpınar (2019)
6. Effect of special Hungarian probiotic kefir on faecal microflora
   Mária Figler, Gyula Mózsik, Béla Schaffer, Beáta Gasztonyi, Pongrác Acs (2006)
7. A randomized clinical trial measuring the influence of kefir on antibiotic-associated diarrhea: the measuring the influence of Kefir (MILK) Study
   Daniel J Merenstein, Jennifer Foster, Frank D'Amico (2009)
8. Kefir Is a Viable Exercise Recovery Beverage for Cancer Survivors Enrolled in a Structured Exercise Program
   Peter Smoak, Nicholas Harman, Victoria Flores, Jacob Kisiolek, Nicholas A Pullen (2021)
9. Effects of kefir or milk supplementation on zonulin in overweight subjects
   Z Jenko Pražnikar, S Kenig, T Vardjan, M Černelič Bizjak, A Petelin (2020)
10. Effect of kefir on the quality of life of patients being treated for colorectal cancer
    Gulbeyaz Can, Erkan Topuz, Duygu Derin, Zehra Durna, Adnan Aydiner (2009)
11. Effect of oral administration of kefir on serum proinflammatory cytokines on 5-FU induced oral mucositis in patients with colorectal cancer
    E Topuz, D Derin, G Can, E Kürklü, S Cinar (2008)
12. Kefir improves the efficacy and tolerability of triple therapy in eradicating Helicobacter pylori
    Onder Bekar, Yusuf Yilmaz, Macit Gulten (2011)
13. Short-Term Effects of Kefir-Fermented Milk Consumption on Bone Mineral Density and Bone Metabolism in a Randomized Clinical Trial of Osteoporotic Patients
    Min-Yu Tu, Hsiao-Ling Chen, Yu-Tang Tung, Chao-Chih Kao, Fu-Chang Hu (2015)
14. Effects of probiotics on salivary Streptecoccus mutans and Lactobacillus levels in orthodontic patients
    Sevtap Alp, Zeliha Müge Baka (2018)
15. Comparative study of Kefir yogurt-drink and sodium fluoride mouth rinse on salivary mutans streptococci
    Maryam Ghasempour, Seyyed Ali Asghar Sefdgar, Ali Akbar Moghadamnia, Reza Ghadimi, Samane Gharekhani (2014)
16. [The effect of kefir consumption on human immune system: a cytokine study]
    Ali Kudret Adiloğlu, Nurettin Gönülateş, Mehmet Işler, Altuğ Senol (2013)
17. The effects of postexercise consumption of a kefir beverage on performance and recovery during intensive endurance training
    K V O'Brien, L K Stewart, L A Forney, K J Aryana, W Prinyawiwatkul (2015)
18. Effects of a kefir supplement on symptoms, colonic transit, and bowel satisfaction score in patients with chronic constipation: a pilot study
    İlker Turan, Özden Dedeli, Serhat Bor, Tankut İlter (2014)